Oral fosfomycin for treatment of urinary tract infection: a retrospective cohort study

[1] Foxman B(2014)Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden Infect Dis Clin North Am 28 1-13

[2] Flores-Mireles AL(2015)Urinary tract infections: epidemiology, mechanisms of infection and treatment options Nat Rev Microbiol 13 269-284

[3] Walker JN(2014)A new strategy to fight antimicrobial resistance: the revival of old antibiotics Front Microbiol 5 551-1684

[4] Caparon M(2015)Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial BMJ Open 5 e007363-340

[5] Hultgren SJ(2014)Diagnosis and management of urinary tract infections in the outpatient setting: a review Jama 312 1677-857

[6] Cassir N(2011)Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy Infection 39 333-290

[7] Rolain JM(2014)Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 34 845-30

[8] Brouqui P(2007)Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model J Infect Chemother 13 285-65

[9] Rosso-Fernandez C(2015)Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urology annals 7 26-357

[10] Sojo-Dorado J(2007)Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections Int J Antimicrob Agents 29 62-684

[1] Foxman B(2014)Urinary tract infection syndromes: occurrence, recurrence, bacteriology, risk factors, and disease burden Infect Dis Clin North Am 28 1-13

[2] Flores-Mireles AL(2015)Urinary tract infections: epidemiology, mechanisms of infection and treatment options Nat Rev Microbiol 13 269-284

[3] Walker JN(2014)A new strategy to fight antimicrobial resistance: the revival of old antibiotics Front Microbiol 5 551-1684

[4] Caparon M(2015)Fosfomycin versus meropenem in bacteraemic urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli (FOREST): study protocol for an investigator-driven randomised controlled trial BMJ Open 5 e007363-340

[5] Hultgren SJ(2014)Diagnosis and management of urinary tract infections in the outpatient setting: a review Jama 312 1677-857

[6] Cassir N(2011)Extended-spectrum beta-lactamase-producing Gram-negative pathogens in community-acquired urinary tract infections: an increasing challenge for antimicrobial therapy Infection 39 333-290

[7] Rolain JM(2014)Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the Society of Infectious Diseases Pharmacists Pharmacotherapy 34 845-30

[8] Brouqui P(2007)Treatment of Pseudomonas aeruginosa biofilms with a combination of fluoroquinolones and fosfomycin in a rat urinary tract infection model J Infect Chemother 13 285-65

[9] Rosso-Fernandez C(2015)Increasing antimicrobial resistance among uropathogens: Is fosfomycin the answer? Urology annals 7 26-357

[10] Sojo-Dorado J(2007)Fosfomycin in the treatment of extended spectrum beta-lactamase-producing Escherichia coli-related lower urinary tract infections Int J Antimicrob Agents 29 62-684